ESR1 and triple-negative breast carcinoma: Triple-negative breast cancer, hallmarked by tumors that lack estrogen receptor (ER), progesterone receptor (PR), and HER-2 genes, represent significant clinical challenge as these cancers are highly aggressive and are resistant to conventional endocrine therapy and suffers lack of targeted therapies [3].